Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05985915
Other study ID # CVAY736A2301E1
Secondary ID 2022-502966-26
Status Recruiting
Phase Phase 3
First received
Last updated
Start date October 27, 2023
Est. completion date July 18, 2030

Study information

Verified date June 2024
Source Novartis
Contact Novartis Pharmaceuticals
Phone 1-888-669-6682
Email novartis.email@novartis.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to measure the long-term safety and tolerability of ianalumab in participants with Sjogrens syndrome who have previously completed treatment from one of two NEPTUNUS 1 year core studies (CVAY736A2301 or CVAY736A2302). - The study treatment is ianalumab 300 mg in a 2 mL pre-filled syringe for injection. All participants will receive ianalumab either monthly or every 3 months. - The treatment duration will be 3 years with an additional up to 2-year safety follow-up. The total duration of this extension study will be up to 5 years. - The visit frequency will be monthly during both the treatment period and mandatory follow-up, and then less frequently during the subsequent conditional follow-up Treatment of interest: The randomized treatment (ianalumab) will be received monthly or every 3 months. Participants assigned to treatment every 3 months will receive placebo every month between the ianalumab doses to maintain blinding. Number of Participants: Approximately 600 participants from the NEPTUNUS core studies will be rolled over into the extension study. Treatment Groups:There will be no screening period in this trial. From Week 48 of the NEPTUNUS core study, participants will be given the opportunity to consent to this extension study. From Week 52 of the NEPTUNUS core studies (i.e., Day 1 in the extension study), eligible participants will be assigned to either one of the treatment regimens: - ianalumab 300 mg monthly or - ianalumab 300 mg once every 3 months Participants receiving placebo in either of the NEPTUNUS core studies will be randomized 1:1 to receive ianalumab 300 mg monthly or every 3 months starting from Week 60 and participants receiving ianalumab in either of the NEPTUNUS core studies will continue the same treatment in the extension study. Ianalumab will be given as a subcutaneous injection from a 2 mL pre-filled syringe. Participants will be given the opportunity to self-inject at home on some visits after receiving training.


Description:

The primary purpose of this 3-year treatment extension study is the continued evaluation of the safety and tolerability of treatment with ianalumab 300 mg monthly or every 3 months. An additional purpose is to explore the long-term efficacy of both dosing regimens of ianalumab 300 mg. The Primary Objective is to assess the long-term safety and tolerability of ianalumab in participants with Sjogrens syndrome. Secondary objectives are as follows, To evaluate the long-term efficacy of VAY736 300 mg administered monthly or every 3 months. To show comparability of ianalumab Ctrough between 2x 1mL PFS (from the NEPTUNUS core studies: CVAY736A2301 and CVAY736A2302) and 1x 2mL PFS for participants on continuous monthly treatment. To further assess the pharmacokinetics of ianalumab. To assess the impact of long-term treatment on B-cell depletion. Trial Design: This is a multicenter, randomized, double-blind, phase 3b study to assess the long-term safety and tolerability of four treatment regimens of ianalumab in participants with Sjogrens syndrome who have taken part in and completed one of two NEPTUNUS core studies, NEPTUNUS-1 (CVAY736A2301) or NEPTUNUS-2 (CVAY736A2302). There will be no screening period in this trial. From week 48 of the NEPTUNUS core study, participants will be given the opportunity to consent to this extension study. Eligible participants will continue their assigned treatment to receive ianalumab 300 mg either monthly or every 3 months for up to 3 additional years of treatment beyond the 1-year core study period. After the treatment period, all participants will enter a follow-up period to be monitored for at least 20 weeks and then a conditional (if B-cell recovery criteria have not been met) follow-up period. The total post treatment follow-up period is up to 2 years. Study Population: Participants with Sjogrens syndrome who have completed treatment in one of two NEPTUNUS core studies. Method of blinding: Double-blind Study treatment assignment method: Participants randomized to ianalumab 300 mg monthly or every 3 months in one of the NEPTUNUS core studies will continue their assigned treatment. Participants randomized to placebo in the NEPTUNUS core studies will be randomized in a 1:1 ratio to either ianalumab 300 mg monthly or every 3 months. Participants randomized to ianalumab 300 mg every 3 months will receive placebo (a dummy treatment) once monthly between doses. Committees: An independent Data Monitoring Committee (DMC) will be utilized for safety review throughout the study. A steering committee will be formed to ensure overview of the study conduct.


Recruitment information / eligibility

Status Recruiting
Enrollment 600
Est. completion date July 18, 2030
Est. primary completion date August 21, 2028
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: 1. Signed informed consent prior to participation in the extension study. 2. Participants must have participated in either one of the two NEPTUNUS core studies, CVAY736A2301 or CVAY736A2302, and must have completed the entire treatment up to Week 48 without treatment discontinuation in core NEPTUNUS studies. 3. In the judgement of the Investigator, participants must be expected to clinically benefit from continued ianalumab therapy. Exclusion Criteria: 1. Use of therapies excluded by the NEPTUNUS-1 and NEPTUNUS-2 study protocols (see NEPTUNUS studies protocols exclusion criteria in Section 5.2 for details). 2. Plans for administration of live vaccines during the study period. 3. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive human Chorionic Gonadotropin (hCG) laboratory test. 4. Women of child-bearing potential (WOCBP), defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception while taking study treatment during dosing and for 6 months after stopping of investigational drug. Highly effective contraception methods include: - Total abstinence (when this is in line with the preferred and usual lifestyle of the participant. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception. - Female bilateral tubal ligation, female sterilization (have had surgical bilateral oophorectomy with or without hysterectomy) or total hysterectomy at least six weeks before taking study treatment. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment. - Male sterilization (at least 6 months prior to screening). For female participants on the study, the vasectomized male partner should be the sole partner for that participant. - Use of oral (estrogen and progesterone), injected, or implanted hormonal methods of contraception or placement of an intrauterine device (IUD) or intrauterine system (IUS), or other forms of hormonal contraception that have comparable efficacy (failure rate < 1%), for example hormone vaginal ring or transdermal hormone contraception. In case of use of oral contraception women should have been stable on the same pill for a minimum of 3 months before taking study treatment. Contraception should be used in accordance with locally approved prescribing information of concomitant medications administered. Women are considered post-menopausal if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g., age-appropriate history of vasomotor symptoms). Women are considered of not child-bearing potential if they are post-menopausal or have had surgical bilateral oophorectomy (with or without hysterectomy), total hysterectomy or bilateral tubal ligation at least six weeks ago. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow-up hormone level assessment is she considered not of child-bearing potential. If local regulations deviate from the contraception methods listed above to prevent pregnancy, local regulations apply and will be described in the informed consent form (ICF). 5. Sexually active males unless they agree to use barrier protection during intercourse while taking study treatment are excluded. As condom use alone has a reported failure rate exceeding 1% per year, it is recommended female partners of male study participants use a second method of birth control. Although ianalumab is not teratogenic and/or genotoxic, and not transferred to semen, male contraception is required, as requested by FDA.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Ianalumab (VAY736)
VAY736 300 mg /2 mL, PFS, Solution for injection for subcutaneous use
Other:
Placebo
Placebo 0 mg/2 mL, PFS, Solution for injection for subcutaneous Use

Locations

Country Name City State
Argentina Novartis Investigative Site Buenos Aires
Argentina Novartis Investigative Site Ciudad Autonoma de Bs As Buenos Aires
Argentina Novartis Investigative Site Quilmes Buenos Aires
Argentina Novartis Investigative Site Tucuman San Miguel De Tucuman
Australia Novartis Investigative Site Hobart Tasmania
Australia Novartis Investigative Site Maroochydore Queensland
Australia Novartis Investigative Site Woodville South Australia
Austria Novartis Investigative Site Graz
Belgium Novartis Investigative Site Leuven
Brazil Novartis Investigative Site Juiz de Fora MG
Brazil Novartis Investigative Site Salvador BA
Brazil Novartis Investigative Site Sao Paulo SP
Bulgaria Novartis Investigative Site Burgas
Canada Novartis Investigative Site Sherbrooke Quebec
Canada Novartis Investigative Site Trois Rivieres Quebec
Colombia Novartis Investigative Site Bogota
Czechia Novartis Investigative Site Brno
Czechia Novartis Investigative Site Uherske Hradiste
France Novartis Investigative Site Angers Cedex 9
France Novartis Investigative Site Brest
France Novartis Investigative Site Le Kremlin Bicetre
France Novartis Investigative Site Saint Etienne
Germany Novartis Investigative Site Berlin
Germany Novartis Investigative Site Dresden
Germany Novartis Investigative Site Erlangen
Germany Novartis Investigative Site Freiburg
Germany Novartis Investigative Site Hannover
Germany Novartis Investigative Site Herne
Germany Novartis Investigative Site Ludwigshafen
Germany Novartis Investigative Site Wuerzburg
Guatemala Novartis Investigative Site Guatemala
Guatemala Novartis Investigative Site Guatemala City
Hungary Novartis Investigative Site Debrecen
Hungary Novartis Investigative Site Gyula
Hungary Novartis Investigative Site Szeged
Hungary Novartis Investigative Site Szekesfehervar Fejer
Israel Novartis Investigative Site Kfar Saba
Israel Novartis Investigative Site Ramat Gan
Italy Novartis Investigative Site Milano MI
Italy Novartis Investigative Site Salerno SA
Japan Novartis Investigative Site Chuo ku Tokyo
Japan Novartis Investigative Site Kitakyushu-city Fukuoka
Japan Novartis Investigative Site Kurashiki Okayama
Japan Novartis Investigative Site Meguro-ku Tokyo
Japan Novartis Investigative Site Nagoya Aichi
Japan Novartis Investigative Site Nagoya Aichi
Japan Novartis Investigative Site Sapporo city Hokkaido
Japan Novartis Investigative Site Sasebo-city Nagasaki
Japan Novartis Investigative Site Shinjuku-ku Tokyo
Japan Novartis Investigative Site Yokohama Kanagawa
Lithuania Novartis Investigative Site Vilnius
Poland Novartis Investigative Site Bydgoszcz
Poland Novartis Investigative Site Krakow
Poland Novartis Investigative Site Poznan Wielkopolskie
Poland Novartis Investigative Site Warszawa
Poland Novartis Investigative Site Wroclaw
Poland Novartis Investigative Site Wroclaw Dolnoslaskie
Poland Novartis Investigative Site Wroclaw Dolnoslaskie
Portugal Novartis Investigative Site Guarda
Portugal Novartis Investigative Site Lisboa
Portugal Novartis Investigative Site Lisboa
Portugal Novartis Investigative Site Lisboa
Romania Novartis Investigative Site Cluj-Napoca
Slovakia Novartis Investigative Site Bratislava
Slovakia Novartis Investigative Site Kosice
Slovakia Novartis Investigative Site Zvolen
Spain Novartis Investigative Site Badalona Catalunya
Spain Novartis Investigative Site Bilbao Pais Vasco
Spain Novartis Investigative Site La Coruna Galicia
Spain Novartis Investigative Site Madrid
Spain Novartis Investigative Site Sabadell Barcelona
Spain Novartis Investigative Site Santander Cantabria
Spain Novartis Investigative Site Vigo Pontevedra
Sweden Novartis Investigative Site Stockholm SE
Taiwan Novartis Investigative Site Kaohsiung
Taiwan Novartis Investigative Site Taichung
Taiwan Novartis Investigative Site Taichung
Turkey Novartis Investigative Site Ankara
United Kingdom Novartis Investigative Site Leeds
United Kingdom Novartis Investigative Site Liverpool
United Kingdom Novartis Investigative Site Newcastle Upon Tyme
United States Ochsner Health System Baton Rouge Louisiana
United States Bay Area Arthritis And Osteoporosis Brandon Florida
United States STAT Research Inc . Dayton Ohio
United States North GA Rheumatology Group, PC CAIN457FUS01 Duluth Georgia
United States Prolato Clinical Research Center Houston Texas
United States Houston Rheumatology & Arthrit Katy Texas
United States Advanced Medical Research La Palma California
United States Arthritis Osteoporosis Assoc of NM Las Cruces New Mexico
United States RAO Research LLS Oklahoma City Oklahoma
United States Clin Invest Specialists Inc Orland Park Illinois
United States St Lawrence Health System Potsdam New York
United States Arthritis Northwest PLLC Spokane Washington
United States Advanced Rheumatology of Houston Spring Texas
United States West Broward Rheumatology Assoc Inc Tamarac Florida

Sponsors (1)

Lead Sponsor Collaborator
Novartis Pharmaceuticals

Countries where clinical trial is conducted

United States,  Argentina,  Australia,  Austria,  Belgium,  Brazil,  Bulgaria,  Canada,  Colombia,  Czechia,  France,  Germany,  Guatemala,  Hungary,  Israel,  Italy,  Japan,  Lithuania,  Poland,  Portugal,  Romania,  Slovakia,  Spain,  Sweden,  Taiwan,  Turkey,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Treatment-emergent AEs (TEAEs)/SAEs Assessment of Safety and tolerability of ianalumab (VAY736) in patients with active Sjogrens syndrome Week 52 to Week 304
Secondary ESSDAI change from baseline EULAR Sjogren's syndrome disease activity index (ESSDAI) is a validated clinical disease outcome measure for Sjogrens that will be used in the study The instrument contains 12 organ-specific domains contributing to assessment of disease activity. For each domain, features of disease activity are scored by a clinician in 3 or 4 (Level 0=No disease activity to Level 3= high disease activity) levels according to their severity. These scores are then summed across the 12 domains in a weighted manner to provide the total score. The maximum possible score is 123.To calculate ESSDAI, all 12 organ domains must be individually assessed by a trained assessor (study Investigator) at every scheduled timepoint. This is to evaluate the long-term efficacy of VAY736 300 mg administered monthly or every 3 months. Over time up to Week 204
Secondary Proportion of participants achieving ESSPRI = 3 AND = 1.5 points reduction from baseline The EULAR Sjogren's Syndrome Patient Reported Index (ESSPRI) questionnaire consists of three items to be given an activity level score between 0-10: pain (joint and/or muscle pain), fatigue and dryness (0 = no symptom at all and 10 = worst symptom imaginable
ESSPRI is an established disease outcome measure for Sjogrens. It consists of three domains of dryness, pain and fatigue. The participant will assess severity of symptoms they experience on a single 0-10 numerical scale for each of the three domains. The ESSPRI score is defined as a mean of scores from the three scales: (dryness + pain + fatigue) /3.
Over time up to Week 204
Secondary Proportion of participants achieving meaningful improvement in the SSSD score The Sjogrens Syndrome Symptom Diary (SSSD) is questionnaire consists of five (six for females) questions about symptoms of Sjögren's syndrome, each question given a score of 0-10 (0=no symptoms, 10=worst possible symptoms) where patient choose the one response that best describes how severe the symptom was at its worst in the PAST 24 HOURS. It includes six symptom items (eye dryness, mouth dryness, skin dryness, physical fatigue, muscle and/or joint pain, genital dryness), and applies a recall period of 24 hrs. The aim of the SSSD is to establish patient reported endpoints for the treatment of Sjogrens syndrome. Participants will complete the diary daily for 7 days prior to the scheduled dosing. Over time up to Week 204
Secondary Pre-dose Ianalumab serum concentrations To show comparability of ianalumab Ctrough between 2x 1 mL PFS (from the NEPTUNUS core studies: CVAY736A2301 and CVAY736A2302) and 1x 2 mL PFS for participants on continuous monthly treatment. pre-dose (i.e., Ctrough) at Week 52 and Week 64
Secondary On-treatment Ianalumab serum concentrations To further assess the pharmacokinetics of ianalumab. During treatment (e.g., Ctrough) i.e. from Week 52 to Week 204 and follow-up i.e. 304, after last dose.
Secondary B-cell count measurement To assess impact of long-term treatment on B-cell depletion. Week 52 to Week 304
See also
  Status Clinical Trial Phase
Completed NCT01470638 - A Study of Flt3-Ligand Levels in Sjögrens Syndrome